Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An epidemic of non-A, non-B hepatitis (NANBH) occurred in plasmapheresis donors in Guan county, Hebei province in 1985. NANBH was diagnosed by epidemiological studies and serological exclusion of HAV, HBV, and other virus infections. Recently, 163 sera of 108 patients with NANBH and 65 sera of 49 cases with elevated alanine aminotransferase (ALT) levels collected during the epidemic were tested at the Disease Control Center, U. S. A. by anti- HCV EIA (Chiron C 100). The positive rates for anti-HCV in these two groups were 89.8% (97/108) and 93.9% (46/49), respectively, with an average rate of 90.8% The figures increased with duration of illness and persistence of ALT elevation, i.e 17.6% and 55.6% within 1 month, 88.9% and 87.5% at 6 months, 100% and 100% after 2 years, respectively. Five patients with NANBH and one case with elevated ALT levels were followed up for 3 to 4 years. It was found that anti-HCV remained positive even after the patients had recovered and their ALT levels returned to normal.
 ...
PMID:[A serological study on hepatitis C infection in plasma donors]. 212 17

The type and predicting factors of response to alpha interferon therapy have been studied in 26 patients with chronic non-A non-B hepatitis. Interferon was administered three times weekly during 6 months at a dose of 3 millions units/day. Eleven patients (42 percent) had serum alanine aminotransferase levels below 1.5 times the upper limit of normal range at the end of treatment. Only eight (31 percent) patients had persistent normalization of seric alanine aminotransferase value, 6 months after the end of the interferon treatment. The main factors involved in the response to therapy were age, apparent duration of the disease, and mode of contamination: patients who responded to interferon were younger, had a shorter duration of hepatitis and a parenterally transmitted disease.
 ...
PMID:[Interferon alpha-2a treatment of 26 patients with chronic non-A non-B hepatitis. Predictive factors of response]. 212 69

To assess the efficacy of therapy with the antiviral agent interferon in chronic hepatitis C (non-A, non-B hepatitis), we randomly assigned 166 chronic hepatitis C patients to treatment with either 3 million or 1 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after 6 months of interferon therapy was 46% in patients treated with 3 million units of interferon (p less than 0.001) and 28% in those treated with 1 million units (p less than 0.02), but only 8% in untreated patients. Serum alanine aminotransferase levels became completely normal in 22 of the 26 patients (85%) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56%) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histological improvement because of the regression of lobular and periportal inflammation. Relapse within 6 months after the completion of treatment occurred in 51% of the patients treated with 3 million units of interferon and 44% of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.
 ...
PMID:Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. 212 85

Eighty patients with chronic non-A, non-B hepatitis completed a randomized controlled trial of the therapeutic efficacy of recombinant interferon alfa-2b. Twenty-nine received 1 million units and 26 received 3 million units of interferon subcutaneously thrice weekly for 6 months, and 25 were controls. Normalization or a significant decrease of alanine aminotransferase values was obtained in 19/29 (66%) patients treated with 1 million units, in 18/26 (69%) patients treated with 3 million units and in one control patient (4%, p less than 0.05). However, when control patients were randomized after the initial 24 weeks to receive 1 or 3 million units of interferon for 48 weeks, 12/14 (86%) patients receiving 3 million units responded to therapy versus 3/11 patients receiving 1 million units (27%, p less than 0.05). After a 1 to 6 months follow-up period post treatment, an alanine aminotransferase relapse was observed in 18/30 (60%) responders to 3 million units and in 17/22 (77%) responders to 1 million units. Cirrhotic patients responded less than patients with non-cirrhotic disease (47 vs. 78%, p less than 0.05). Only responders treated with 3 million units significantly ameliorated their histologic picture (pre-therapy Knodell's index = 8.9, post-therapy = 6.0, p less than 0.05). The data confirm that treatment with interferon is of benefit in patients with chronic non-A, non-B hepatitis.
 ...
PMID:A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. 212 87

Thirty patients with chronic non-A, non-B hepatitis (24 male, six female; median age 38 years, range: 15-68 years) were treated with recombinant interferon alfa-2b for 1 year. Treatment was started with 5 million units interferon alfa-2b daily for 2 weeks followed by 2 million units daily for another 2 weeks. Further doses were titrated according to alanine aminotransferase values. After 1 year, treatment was stopped and a follow-up biopsy was obtained. Thereafter, patients were followed for 6 months. Of the 24 patients who completed the 1-year treatment period, 14 (58%) had normal alanine aminotransferase values at the end of the study, eight of whom showed transient increases while on treatment. In another seven (29%), alanine aminotransferase levels decreased by more than 50% of pre-treatment values but remained above the normal range. Biopsies at the end of treatment showed a complete disappearance of inflammatory activity in four and a marked improvement in eleven other patients. The results of this study indicate that a 1-year treatment with recombinant interferon alfa-2b of patients with non-A, non-B hepatitis was very effective at normalizing or improving serum transaminases and liver histology. However, the overall relapse rate was 57%, with relapse occurring in a greater proportion of patients with temporary breakthroughs during therapy (requiring dosage increase), and particularly of patients with only a partial response to treatment (serum transaminases decreased by greater than or equal to 50%). Thus, further studies are needed to establish the optimal dose and duration of treatment to induce a complete resolution of the disease.
 ...
PMID:One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. 212 88

Thirty-three Swedish patients with chronic post-transfusion non-A, non-B hepatitis entered a randomized trial of interferon alfa-2b treatment (INTRON A, Schering-Plough Corporation) (3 million units, three times weekly, subcutaneously for 36 weeks). Twenty-two patients (67%) were reactive for antibodies against hepatitis C virus. Nineteen patients completed the course of therapy; 11 (58%) had a complete response with normalization of serum alanine aminotransferase levels, compared to none of the 12 controls (p less than 0.001). Four treated patients with chronic active hepatitis were non-responders. Non-responders had a significantly higher mean body weight than responders (p less than 0.05) and tended to have a longer duration of prior disease. During the 10-month follow-up period post treatment, 4/11 (36%) complete responders had a sustained response and three (75%) of these four were reactive for antibodies against hepatitis C virus, whereas 7/11 (64%) relapsed, of whom four (57%) were reactive for antibodies against hepatitis C virus. All patients who were treated again responded but relapsed once more after retreatment was stopped. We conclude that the majority of patients with chronic post-transfusion non-A, non-B hepatitis will respond to 9 months' interferon alfa-2b treatment, but that only one of three responders will have a sustained response 10 months post treatment. Reactivity for antibodies against hepatitis C virus is not predictive of the outcome of therapy.
 ...
PMID:Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. 212 89

The effectiveness of recombinant alpha-interferon was evaluated in chronic non-A, non-B hepatitis of parenteral transmission. Thirty patients were randomly allocated two groups: control group (without treatment) and treatment group (alpha-interferon 5 mega units thrice weekly for 2 months, and then 1.5 mega units until the eighteenth month). Retrospectively, 26 patients had anti-hepatitis C antibodies. After the first month, 40% of the treated patients had normal serum alanine aminotransferase levels, and no one in the control group (p less than 0.05). After 18 months of treatment, 40% (6/15) of treated patients and 7% (1/14) of controls had normal serum transaminases (p less than 0.05). Interferon was well tolerated. A decrease in the Knodell Index score on final biopsy was found in treated patients (p less than 0.05), with no variations in the control group. Relapse within 7 months after the end of treatment occurred in two out of six complete responders. Thus, recombinant alpha-interferon therapy given for 18 months normalizes serum transaminases and improves histological lesions in chronic hepatitis C of parenteral epidemiology. This long-term interferon schedule is well tolerated.
 ...
PMID:Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. 212 90

We have previously described a large municipal obstetrical population in which the carriage rate of hepatitis B (HBV) is 1.2%. The present study was undertaken to determine the effectiveness of our immunoprophylaxis regimen (hepatitis B immune globulin at 36-72 h, hepatitis B vaccine at 36-72 h, 1 month and 6 months) in eliciting protective antibody to hepatitis B surface antigen (anti-HBs) in the infants of these women, the rate of perinatal transmission of HBV in this population prior to vaccination, the prevalence of anti-hepatitis delta antibody (anti-HD), and the prevalence of liver disease in our hepatitis B surface antigen-positive (HBsAg+) population. Four hundred eleven infants of HBsAg+ women were born during the 33-month study period. Of these, only 64 (15.6%) completed the vaccine series and returned for testing at 12 months. Sixty of the 64 had anti-HBs, and one (1.6%) had become HBsAg+. Eighty-nine older siblings of the immunized infants were tested, and 17 (19%) were HBsAg+. Of 54 mothers and eight siblings who were HBsAg+, none had anti-HD. Serum alanine aminotransferase (ALT) levels were normal in 53 of 54 HBsAg+ mothers tested. These data demonstrate 1) reduction of perinatal transmission of HBV from 19% to 1.6% using our protocol, 2) absence of hepatitis delta infection in this population, and 3) high prevalence of asymptomatic carriage of HBV, rather than clinically significant liver disease, in this population. It is imperative to improve compliance in order to maximize the effectiveness of immunoprophylaxis for newborns of HBsAg+ mothers.
 ...
PMID:Hepatitis B infection in a large municipal obstetrical population: characterization and prevention of perinatal transmission. 213 61

Eighteen red-bellied tamarins (Saguinus labiatus), experimentally infected with hepatitis A virus (HAV), were followed for up to 1.5 years after initial challenge. Half of these animals developed protracted alanine aminotransferase (ALT) abnormalities, which lasted for between 23 and 55 weeks post-challenge. IgM anti-HAV was detected intermittently during the early phase of their relapsing hepatitis and never after return of ALT levels to normal. The possibility that these findings may be related to continued HAV replication, coinfection with another agent, or the result of an autoimmune phenomenon triggered by HAV are discussed.
 ...
PMID:Protracted alanine aminotransferase levels in tamarins infected with hepatitis A virus. 215 8

Polypeptides encoded by the pre-S1 and pre-S2 genes of hepatitis B virus (HBV) (pre-S1 antigen and pre-S2 antigen) were detected by enzyme-linked immunosorbent assay (ELISA) in 137 serum samples of patients with HBV infection. The HBV-DNA level closely correlated with the titer of pre-S antigens. However, HBV-DNA levels more closely correlated with the titer of the pre-S1 antigen [HBV-asymptomatic carrier (ASC): n = 40, r = 0.800, P less than 0.01; chronic hepatitis B (CH): n = 60, r = 0.730, P less than 0.01] than with the titer of the pre-S2 antigen [ASC: r = 0.675, P less than 0.01; CH: r = 0.575, P less than 0.01]. Thirty patients with CH, in whom hepatitis e antigen (HBeAg) was cleared after acute exacerbation (AE) [alanine aminotransferase (ALT) level greater than 200 IU/L] and the ALT level normalized, were followed for 12 months and classified into two groups: Group 1, those in whom HBeAg reappeared with an elevated ALT level within 12 months, and Group 2, those in whom HBeAg was persistently cleared from the serum and a normal ALT level continued. Of the 30 patients, 24 (80%) were classified into Group 1 and 6 (20%) were classified into Group 2. Changes in serum levels of HBV markers a month before and after AE were observed. The HBV-DNA level and DNA-P activity became negative after AE in both groups. The titer of pre-S1 antigen also decreased after AE, and no significant differences were observed between Group 1 and Group 2.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection. 217 Feb 20


<< Previous 1 2 3 4 5 6 7 8 9 10